Increased gene copy number of EGFR and overexpression/amplification of HER2 pose the precondition for anti-EGFR and anti-Her2 therapy in breast, colorectal and lung cancer (Wolff et al, 2007; Hirsch et al, 2008; Laurent-Puig et al, 2009). The gene discussed is EGFR; the disease is lung carcinoma.